Wockhardt Ltd
Company Profile
Business description
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
Contact
Bandra-Kurla Complex
Wockhardt Towers
Bandra East
MumbaiMH400051
INDT: +91 2226534444
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,296
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
stocks
Tesla: Board announces new pay package for CEO Elon Musk
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,028.80 | 106.80 | 1.20% |
CAC 40 | 7,621.04 | 10.97 | -0.14% |
DAX 40 | 23,846.07 | 88.38 | 0.37% |
Dow JONES (US) | 44,161.87 | 11.77 | -0.03% |
FTSE 100 | 9,142.73 | 14.43 | 0.16% |
HKSE | 24,902.53 | 169.08 | 0.68% |
NASDAQ | 20,966.65 | 86.93 | -0.41% |
Nikkei 225 | 40,549.54 | 258.84 | 0.64% |
NZX 50 Index | 12,877.04 | 193.00 | 1.52% |
S&P 500 | 6,309.28 | 20.66 | -0.33% |
S&P/ASX 200 | 8,770.40 | 106.70 | 1.23% |
SSE Composite Index | 3,617.60 | 34.29 | 0.96% |